Recombinant Partners with U.S. Department of Veterans Affairs to Complete First Phase of Large Scale Genomics Research Platform

Recombinant Partners with U.S. Department of Veterans Affairs to Complete First Phase of Large Scale Genomics Research Platform
Unprecedented VA research program launched nationally

May 25, 2011 11:37 AM Eastern Daylight Time
NEWTON, Mass.--(EON: Enhanced Online News)--Recombinant Data Corp., a Massachusetts-based healthcare data warehousing and clinical intelligence solutions provider, today announced its continued contributions to innovative IT tools for clinical research, through the company's key role in the U.S. Department of Veterans Affairs' Million Veteran Program (MVP). Under the leadership of VA's Office of Research and Development, Recombinant has partnered with MAVERIC, the VA's Massachusetts Veterans Epidemiology Research and Information Center in the development of the Genomic Informatics System for Integrative Science (GenISIS). GenISIS is the informatics platform for MVP, the VA's initiative launched nationally on May 5, 2011 to recruit one million military veterans to participate in clinical research, and to collect, manage and analyze genomic data on disorders of significance in veterans' health.

Recombinant collaborated with the MAVERIC team to create a system to streamline and integrate key elements of large scale recruitment and enrollment of patients for GenISIS and MVP-communicating with veterans via mail and telephone call centers regarding MVP participation; scheduling research-related appointments in coordination with schedules maintained in VistA (Veterans Health Information Systems and Technology Architecture), the VA's electronic medical record system; collecting and managing patients' research consent and initial clinical trial questionnaire data; and tracking tissue samples collected as part of the research enrollment process.

Recombinant and MAVERIC are continuing to work together on the next phases of GenISIS, which will include the clinical data warehouse integrating genomic data with the clinical data maintained in the VistA EMR, biorepository management, cohort discovery and hypothesis testing tools, and the genomics analysis framework. These are planned for completion later in 2011 and in 2012. In working with the MAVERIC team, Recombinant uses its Agile Iterative Development approach to rapid design and prototyping, and delivering production systems in a just-in-time mode to meet the project's requirements.

The overall goal of GenISIS and MVP is to create a patient recruitment infrastructure and data repository integrating genomic and clinical data, in support of the VA's research to understand the disease mechanisms involved in disorders of importance to veterans' health. In a 2008 survey of U.S. veterans, 83% favored creating a system like GenISIS, and 71% said they would definitely or probably participate.

"Recombinant is pleased to support the U.S. Department of Veterans Affairs in its genomic research program," said Peter Emerson, CEO of Recombinant Data Corp. "GenISIS is a beacon project that many other healthcare providers are looking to emulate, as it will establish a model for secure and efficient analysis of consented genotypic data to move towards the promise of genomics to deliver personalized medicine."

About Recombinant Data Corp.

Recombinant provides leading-edge data warehousing and clinical intelligence solutions to healthcare providers, academic medical centers and life science researchers to deliver higher quality outcomes, accelerate personalized medicine, and lower costs. Our team of industry veterans is focused on improving the flow of reliable data to power clinical and research applications in a secure, compliant environment. For more information about Recombinant's products and services, visit www.recomdata.com.

Contacts
Recombinant Data Corp.
Ken Kiyama, 617-243-3700
[email protected]
or
William Stetson, 617-243-3700
[email protected]

View All Releases from This Organization

 

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.